Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of ?v?3 Integrins Expression as a Biomarker of Angiogenesis

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.

Stanford is now accepting new patients for this trial. Please contact CCTO at 650-498-7061 for more information.

Investigator(s):

Intervention(s):

  • other : laboratory biomarker analysis
  • procedure : positron emission tomography
  • procedure : computed tomography
  • procedure : positron emission tomography
  • procedure : computed tomography
  • radiation : fludeoxyglucose F 18
  • radiation : 2-fluoropropionyl-labeled pegylated dimeric RGD peptide

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Provides written informed consent - Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment - Able to remain still for duration of each imaging procedure (about one hour)

External Links

Stanford Medicine Resources:

Footer Links: